trending Market Intelligence /marketintelligence/en/news-insights/trending/6cCWipz788wfQbF8mUsy5w2 content esgSubNav
In This List

Brazil places $24M order for Protalix's Gaucher disease treatment

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Brazil places $24M order for Protalix's Gaucher disease treatment

Brazil's Ministry of Health placed a $24 million order for Alfataliglicerase with Protalix BioTherapeutics Inc. to treat Gaucher patients in the country.

The company will deliver the drug in three shipments by the end of next year.

The order comes at a time when the company is pushing for Alfataliglicerase to become the preferred therapy for Brazilian Gaucher patients.